Wells Fargo Reiterates Overweight Rating on Ascendis Pharma (ASND)
Tweet Send to a Friend
Wells Fargo analyst Chris M. Carey reiterated an Overweight rating and $289.00 price target ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
